NCT03386162: A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer

NCT03386162
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: PI3K
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have presence of PIK3CA mutation on exon 9 or 20
Exclusions: 
https://ClinicalTrials.gov/show/NCT03386162

Comments are closed.

Up ↑